Ferronova Pty Ltd. has signed a licensing agreement with the Purdue Research Foundation (PRF) for the application of PRF's fibroblast activation protein (FAP) inhibitor in magnetic resonance imaging (MRI) and MRI-guided therapies.
Xnk Therapeutics AB has entered into a research collaboration with the Karolinska University Hospital to evaluate the suitability of the company's preclinical autologous natural killer (NK) cell therapy candidate XNK-02 as a novel therapy for treatment of acute myeloid leukemia (AML).
Adaptative immune response mediated by NKG2D receptor and its ligand NKG2DL could be the clue for CD8-expressing “killer” T cells to kill tumors lacking the major histocompatibility complex (MHC) class I, according to a group of researchers at Duke University.
Fore Biotherapeutics Inc. has closed on a $75 million series D financing so that it can continue developing its lead asset, plixorafenib, an oral small molecule that selectively inhibits BRAF alterations.
The narrative of TIGIT-targeting immunotherapy development, beset by negative news in recent months, has found a positive plotline again, thanks to what Roche Holding AG referred to as “an inadvertent disclosure” of a second interim analysis from the phase III Skyscraper-01 study testing anti-TIGIT candidate tiragolumab with anti-PD-L1 antibody Tecentriq (atezolizumab) in non-small-cell lung cancer.
Verismo Therapeutics Inc., the U.S. subsidiary of South Korea’s HLB Co. Ltd., inked a license agreement with the University of Pennsylvania for two newly discovered CD19 binders – one of which will be used to develop Synkir-310, its investigative CAR T therapy for blood cancers.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors, preferably PARP-1, reported to be useful for the treatment of cancer.
Verismo Therapeutics Inc. has entered into a licensing agreement with the University of Pennsylvania for worldwide exclusive rights for two newly discovered anti-CD19 binders, the result of a sponsored research agreement between the two parties.
Thymidylate synthase (TS) is an enzyme essential for DNA synthesis and cell proliferation and is a potential oncoprotein itself. Consequently, TS is considered a molecular target for malignant tumors.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
